文献速递肝病

血清HBcrAg水平可分层慢性乙肝中间病毒载量患者的疾病进展风险

Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load.
PubMed 文献 · Aliment Pharmacol Ther · 2021-01-19

本研究纳入1673例未治疗、非肝硬化、HBeAg阴性且ALT正常的慢性HBV感染者,随访平均15.9年,发现基线HBcrAg水平较高与肝硬化、肝硬化相关并发症及肝病死亡风险增加相关。

要点

  • HBeAg阴性、ALT正常患者中,高HBcrAg水平与肝硬化风险增加相关
  • 中间病毒载量患者中,HBcrAg≥10 KU/mL的肝硬化风险比为3.22
  • HBcrAg<10 KU/mL可定义中间病毒载量患者的低风险组

核心结论

  • 在HBeAg阴性且ALT正常的慢性HBV感染者中,较高的HBcrAg水平与肝硬化风险增加相关。
  • 在中间病毒载量患者中,HBcrAg<10 KU/mL定义了一个疾病进展低风险组。

研究设计与样本

  • 研究纳入1673例未治疗、非肝硬化、HBeAg阴性且基线ALT<40 U/L的慢性HBV感染者。
  • 平均随访15.9年,分析基线HBcrAg水平与肝硬化发生的关系。

主要发现

  • 1673例患者中,104例在平均15.9年随访后发生肝硬化。
  • 较高的HBcrAg水平与肝硬化、肝硬化相关并发症及肝病死亡发生率增加相关。
  • 在445例中间病毒载量患者中,以HBcrAg 10 KU/mL分层的肝硬化风险比为3.22(95%CI 1.61-6.47)。

关键数值与推荐

  • HBcrAg分层阈值为10 KU/mL。
  • 中间病毒载量患者中,HBcrAg≥10 KU/mL vs <10 KU/mL的肝硬化风险比为3.22(95%CI 1.61-6.47)。

临床怎么用

  • 对于HBeAg阴性、ALT正常且病毒载量中等的慢性乙肝患者,可检测HBcrAg以进一步分层肝硬化风险。
  • HBcrAg<10 KU/mL的中间病毒载量患者可视为疾病进展低风险组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core-related antigen (HBcrAg) is a new biomarker for intrahepatic templates for HBV replication. AIM: To explore whether a high HBcrAg level is associated with increased risk of cirrhosis, especially in patients with intermediate viral load (HBV DNA 2000-19 999 IU/mL) due to their moderate risk of disease progression. METHODS: A total of 1673 treatment-naïve, non-cirrhotic patients with negative hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) level <40 U/L at baseline were enrolled. We explored the relationship between baseline levels of HBcrAg and cirrhosis development in all patients, and whether a higher HBcrAg level (<10 vs ≥10 KU/mL) was associated with an increased risk of disease progression in those with intermediate viral load. RESULTS: Of the 1673 patients, 104 developed cirrhosis after a mean follow-up of 15.9 years. Higher HBcrAg levels were associated with increased incidence of cirrhosis, cirrhosis-related complications, and liver-related death. In 445 patients with intermediate viral load, the cirrhosis risk stratified by HBcrAg level of 10 KU/mL yielded a hazard ratio of 3.22 (95% CI: 1.61-6.47). The risk stratification remained significant when exploring other pre-cirrhosis endpoints, including HBeAg-negative hepatitis, hepatitis flare, and HBV DNA >20 000 IU/mL after 3 years of follow-up. CONCLUSIONS: In HBeAg-negative patients with normal ALT levels, higher HBcrAg levels are associated with increased risk of cirrhosis. Among those with intermediate viral load, HBcrAg <10 KU/mL defines a low-risk group for disease progression.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tseng TC, Liu CJ, Yang WT, et al. Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. Aliment Pharmacol Ther. 2021. PMID: 33465271. doi:10.1111/apt.16266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。